beta-Blocker use following myocardial infarction: low prevalence of evidence-based dosing.

[1]  K. Kotseva,et al.  EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries , 2009, European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology.

[2]  Stephen A. Martin,et al.  A Reengineered Hospital Discharge Program to Decrease Rehospitalization , 2009, Annals of Internal Medicine.

[3]  Denis Xavier,et al.  Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): a randomised controlled trial , 2008, The Lancet.

[4]  Helen Y. Lee,et al.  Use of Secondary Prevention Drug Therapy in Patients With Acute Coronary Syndrome After Hospital Discharge , 2008, Journal of managed care pharmacy : JMCP.

[5]  A. Dyer,et al.  Post-myocardial infarction beta-blocker therapy: the bradycardia conundrum. Rationale and design for the Pacemaker & beta-blocker therapy post-MI (PACE-MI) trial. , 2008, American heart journal.

[6]  Harlan M. Krumholz,et al.  ACC/AHA 2008 performance measures for adults with ST-elevation and non-ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures (Writing Committee to Develop Performance Measures for ST-Elevation and Non-ST-Eleva , 2006, Journal of the American College of Cardiology.

[7]  P. Poole‐Wilson,et al.  Tolerability and dose-related effects of nebivolol in elderly patients with heart failure: data from the Study of the Effects of Nebivolol Intervention on Outcomes and Rehospitalisation in Seniors with Heart Failure (SENIORS) trial. , 2007, American heart journal.

[8]  Harlan M Krumholz,et al.  Impact of medication therapy discontinuation on mortality after myocardial infarction. , 2006, Archives of internal medicine.

[9]  L. Køber,et al.  Long-term compliance with beta-blockers, angiotensin-converting enzyme inhibitors, and statins after acute myocardial infarction. , 2006, European heart journal.

[10]  Elizabeth R DeLong,et al.  Association between hospital process performance and outcomes among patients with acute coronary syndromes. , 2006, JAMA.

[11]  Jane A. Linderbaum,et al.  ACC/AHA clinical performance measures for adults with ST-elevation and non-ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures (Writing Committee to Develop Performance Measures on ST-Elevation and Non-ST-El , 2006, Circulation.

[12]  R. Collins,et al.  Early intravenous then oral metoprolol in 45 852 patients with acute myocardial infarction: randomised placebo-controlled trial , 2005, The Lancet.

[13]  P. Poole‐Wilson,et al.  Influence of heart rate, blood pressure, and beta-blocker dose on outcome and the differences in outcome between carvedilol and metoprolol tartrate in patients with chronic heart failure: results from the COMET trial. , 2005, European heart journal.

[14]  Lippincott Williams Wilkins,et al.  ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction , 2004 .

[15]  G. Lamas,et al.  ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction--executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1999 guidelines for the management of patients wi , 2004, Journal of the American College of Cardiology.

[16]  B. Fagerberg,et al.  Dose of metoprolol CR/XL and clinical outcomes in patients with heart failure: analysis of the experience in metoprolol CR/XL randomized intervention trial in chronic heart failure (MERIT-HF). , 2002, Journal of the American College of Cardiology.

[17]  H. Dargie,et al.  Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial , 2001, The Lancet.

[18]  V. Boyko,et al.  The prognosis of a first Q-wave versus non-Q-wave myocardial infarction in the reperfusion era. , 2000, The American journal of medicine.

[19]  Y Wang,et al.  Do "America's Best Hospitals" perform better for acute myocardial infarction? , 1999, The New England journal of medicine.

[20]  J S Alpert,et al.  1999 update: ACC/AHA Guidelines for the Management of Patients With Acute Myocardial Infarction: Executive Summary and Recommendations: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction) , 1999, Circulation.

[21]  P. Rochon,et al.  Prescribing for seniors: neither too much nor too little. , 1999, JAMA.

[22]  J. Ferrières,et al.  Treatment of acute myocardial infarction by primary coronary angioplasty or intravenous thrombolysis in the "real world": one-year results from a nationwide French survey. , 1999, Circulation.

[23]  CIBIS-II Investigators and Committees.  The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial , 1999, The Lancet.

[24]  A. Kadish,et al.  Nonsustained ventricular tachycardia in the setting of acute myocardial infarction: tachycardia characteristics and their prognostic implications. , 1998, Circulation.

[25]  K. Lee,et al.  Atenolol use and clinical outcomes after thrombolysis for acute myocardial infarction: the GUSTO-I experience. Global Utilization of Streptokinase and TPA (alteplase) for Occluded Coronary Arteries. , 1998, Journal of the American College of Cardiology.

[26]  S. Gottlieb,et al.  Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. , 1998, The New England journal of medicine.

[27]  H. Krumholz,et al.  National use and effectiveness of beta-blockers for the treatment of elderly patients after acute myocardial infarction: National Cooperative Cardiovascular Project. , 1998, JAMA.

[28]  S. Viskin,et al.  β-Blocker Dosages and Mortality After Myocardial Infarction: Data From a Large Health Maintenance Organization , 1998 .

[29]  S. Viskin,et al.  Beta-blocker dosages and mortality after myocardial infarction: data from a large health maintenance organization. , 1998, Archives of Internal Medicine.

[30]  高木 純人,et al.  Cedars-Sinai Medical Center アメリカにおける腹腔鏡下外科手術 , 1998 .

[31]  F. Avanzini,et al.  Use of beta-blocking agents in secondary prevention after myocardial infarction: a case for evidence-based medicine? GISSI experience, 1984-1993. The Gruppo Italiano di Studio sulla Sopravvivenza nell'Infarto Miocardico (GISSI) Investigators. , 1997, European heart journal.

[32]  L Goldman,et al.  Adverse Outcomes of Underuse of β-Blockers in Elderly Survivors of Acute Myocardial Infarction , 1997 .

[33]  K. Adams,et al.  Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators. , 1996, Circulation.

[34]  A. Folsom,et al.  Recent trends in acute coronary heart disease--mortality, morbidity, medical care, and risk factors. The Minnesota Heart Survey Investigators. , 1996, The New England journal of medicine.

[35]  D. Brand,et al.  Cardiologists' practices compared with practice guidelines: use of beta-blockade after acute myocardial infarction. , 1995, Journal of the American College of Cardiology.

[36]  S. Viskin,et al.  Treatment with beta-adrenergic blocking agents after myocardial infarction: from randomized trials to clinical practice. , 1995, Journal of the American College of Cardiology.

[37]  C. Furberg,et al.  Effects of prophylactic antiarrhythmic drug therapy in acute myocardial infarction. An overview of results from randomized controlled trials. , 1993, JAMA.

[38]  F. Klocke,et al.  ACC/AHA guidelines for the early management of patients with acute myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (subcommittee to develop guidelines for the early manag , 1990, Circulation.

[39]  T. Pedersen.  Six-year follow-up of the Norwegian multicenter study on timolol after myocardial infarction. , 1986 .

[40]  T. Pedersen.  Six-year follow-up of the Norwegian Multicenter Study on Timolol after Acute Myocardial Infarction. , 1985, The New England journal of medicine.

[41]  P. Hoff,et al.  One year's treatment with propranolol after myocardial infarction: preliminary report of Norwegian multicentre trial. , 1982, British medical journal.

[42]  A randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality results. , 1982, JAMA.

[43]  K. Swedberg,et al.  EFFECT ON MORTALITY OF METOPROLOL IN ACUTE MYOCARDIAL INFARCTION A Double-blind Randomised Trial , 1981, The Lancet.

[44]  Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. , 1981, The New England journal of medicine.